The OJC Episode 26: IASLC World Conference on Lung Cancer Part 2

Pinterest LinkedIn Tumblr +

The second Special Episode dedicated to IASLC World Conference on Lung Cancer

This week we wrap up our coverage of the IASLC World Conference on Lung Cancer.

We hear from Anna Nowak who chats to Craig Underhill about the CONFIRM trial exploring nivolumab versus placebo in relapsed malignant mesothelioma. We have in-depth analysis from Ben Solomon on sotorasib and TRIDENT. Tim Clay talks us through ITACA and LCMC3, and we wrap up our coverage with an interview on the TALENT study with Gilberto Lopes from the University of Miami and Editor of ASCO’s JCO Global Oncology journal. 

Thanks to everyone who participated and thanks to all our listeners, we hope you enjoy today’s entertaining and informative episode.

The OJC Episode 25: IASLC World Conference on Lung Cancer Part 1
If you missed the first episode, including music from Mayhemtom aka Tom John, you can listen and view the notes for this here.

About The Oncology Journal Club:

We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.

With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.

The Oncology Journal Club is hosted by Professor Eva Segelov, from Monash University. Eva is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Antwerp, Belgium. We hope you enjoy listening and find this a valuable and entertaining resource.


This Week’s Papers and Links:

  1. Fennell, D, et al. PS01.11.  Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial. Access online here.
  2. The International Mesothelioma Interest Group
  3. Li, B.T., et al. PS01.07. CodeBreaK 100: Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutated Non-small Cell Lung Cancer. Access online here.
  4. Cho, BC., et al. MA11.07. Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors. Access online here.
  5. Novello, S, et al. PS01.04. International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results. Access online here.  
  6. Lee, JM., et al. P2.04-88. Surgical Outcomes of a Multicenter Phase II Trial of Neoadjuvant Atezolizumab in Resectable Stages IB-IIIB NSCLC: Update on LCMC3 Clinical Trial. Access online here. 
  7. Yang, P-C., et al. PS01.02 – National Lung Cancer Screening Program in Taiwan: The TALENT Study. Access online here.

View the entire WLCL Program in pdf here.

This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.

Find Eva on Twitter: @profevasegelov

Dr Craig Underhill

Craig Underhill

Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

Find Craig on Twitter: @CraigUnderhill

Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology.

Find Hans on Twitter: @HPrenen

 

 

Professor Anna Nowak

Professor Anna Nowak is the current Director of the National Centre for Asbestos Related Diseases (NCARD). She is a Medical Oncologist at Sir Charles Gairdner Hospital (SCGH) and Professor of Medicine at the University of Western Australia (UWA), with research and clinical interests in thoracic cancers and malignant mesothelioma, and neuro-oncology. Her research training includes a laboratory-based PhD thesis in tumour immunology followed by a postdoctoral fellowship in clinical trials and quality of life research, giving her a unique translational perspective with expertise in laboratory science, clinical trials, patient-rated outcomes and quality of life. She was amongst the earliest researchers demonstrating that chemotherapy and immunotherapy could be synergistic treatment modalities in cancer treatment, rather than antagonistic. This belief is now widely held and has directly led to the development of two early phase clinical trials at SCGH, run over the last 5 years, in addition to the national DREAM trial and International DREAM3R trial.

You can find Anna on Twitter: @perth_meso_dr

Professor Ben Solomon

Ben Solomon

Professor Ben Solomon is a medical oncologist in the Lung Service and the Head & Neck service at the Peter MacCallam Cancer Centre in Melbourne, Victoria, Australia. He is the Group Leader of the Molecular Therapeutics and Biomarkers Laboratory in the Research Division. He has an interest in translational lung cancer research and completed a PhD investigating the mechanisms by which EGFR inhibition enhance the effects of radiation, and subsequent postdoctoral studies at the University of Colorado investigating novel predictive markers for therapy with EGFR inhibitors.

Professor Solomon practices as a medical oncologist with a research focus on clinical and translational research in lung cancer and head and neck cancer. His clinical trial work focuses on the identification of novel therapies for lung cancer. The Molecular Therapeutics and Biomarkers Laboratory focuses on pre-clinical studies of novel therapies for cancer and, more specifically, identification of prognostic and predictive biomarkers in lung and head and neck cancers. Find Ben on Twitter: @bensolomon1

Associate Professor Tim Clay

Tim Clay

Dr Tim Clay was born in Subiaco. He completed training in medical oncology at University Hospital Geelong and St Vincent’s Hospital Melbourne. He has completed a doctoral thesis through the University of Melbourne on lung cancer pathology and patient outcomes.

Tim treats adult patients with solid tumours. His areas of interest are lung cancer, breast cancer and urological cancers. He also treats patients with gastrointestinal cancers, head and neck cancer and melanoma.

Tim believes in the importance of research. He is a principal investigator for a number of clinical trials at St John of God Subiaco Hospital. He is the clinical co-chair of the Bendat Respiratory Research and Development Fund contributing to research into lung disease and cancer and mentoring junior clinicians.

Find Tim on Twitter: @drtclay

Professor Gilberto Lopes

Gilberto Lopes, a medical oncologist, is professor of clinical medicine, medical director for international programs and associate director for Global Oncology at the Sylvester Comprehensive Cancer Center at the University of Miami; he also serves as Editor-in-Chief for the American Society of Clinical Oncology’s JCO Global Oncology. He previously worked at the Johns Hopkins University and was chief medical and scientific officer for the Oncoclinicas Group, the largest oncology provider in Latin America with 35 clinics and more than 300 oncologists in nine states in Brazil. His overarching mission is to improve cancer care and control around the world. As a lead investigator in the study Keynote 42, Gilberto presented the results at ASCO’s plenary session in 2018, leading to FDA extension of approval for pembrolizumab in advanced lung cancer.

Dr. Lopes has published more than 200 papers, delivered lectures around the world and he has been principal, co-Principal Investigator or steering committee member in more than 100 studies and clinical trials.

Dr. Lopes is or has been a committee member for the International Association for the Study of Lung Cancer (IASLC), the European Society of Medical Oncology and the American Society of Clinical Oncology (ASCO), as well as an executive board member for the Latin American Cooperative Oncology Group (LACOG).

Find Gilberto on Twitter here: @GlopesMd

Rachael Babin

Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter and Publisher of www.oncologynews.com.au. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter and follow us on Twitter: @OncologyNewsAus

With thanks to Eva Segelov, Craig Underhill, Hans Prenen, Anna Nowak, Ben Solomon, Tim Clay, Gilberto Lopes and Graham Knowles.

Share.

About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.